About Bionovo
     
     
  Company Overview
 
Board of Directors and Management
 
  Scientific Advisory Board
 
  Medical Advisory Board
 
  Careers
 
 

Management and Board of Directors

Management
Name Position Year Joined
Isaac Cohen Chairman of the Board and Chief Executive Officer
2002
Mary Tagliaferri, M.D. President, Chief Medical Officer, Chief Regulatory Officer
2002
David Boyle Senior Vice President and Chief Financial Officer
2012

 
Board of Directors
Name Position Year Elected
Isaac Cohen Chairman of the Board and Chief Executive Officer
2002
Mary Tagliaferri, M.D. President, Chief Medical Officer, Chief Regulatory Officer
2002
Louis Drapeau Lead Director
2008
George C. Butler, Ph.D. Director
2008
Robert Farrell, J.D. Director
2012

Bionovo Management

Isaac Cohen, O.M.D., L.Ac.
Dr. Cohen is a co-founder of Bionovo, Inc., and has served as its Chairman, Chief Executive Officer and Chief Scientific Officer and a Director since February 2002. He became the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer and a Director in April 2005. Mr. Cohen has been a Guest Scientist at the University of California, San Francisco (UCSF) Cancer Research Center and UCSF Center for Reproductive Endocrinology since 1996. Mr. Cohen was in private practice at The American Acupuncture Center, located in Berkeley, California from 1989-2005.

Mary Tagliaferri, M.D., L.Ac.
Dr. Tagliaferri is a co-founder of Bionovo, Inc., and has served as its Chief Regulatory Officer, Chief Medical Officer, Secretary and Treasurer and as a director since February 2002. She became Vice President, Chief Medical Officer, Chief Regulatory Officer, Secretary and Treasurer of Bionovo, Inc. in April 2005, and a Director effective May 2005. She became President of Bionovo, Inc. in addition to continuing her functions as the Company’s Chief Medical Officer, Secretary, Treasurer and Director in May 2007. Dr. Tagliaferri conducted translational research at the University of California, San Francisco from 1996-2002.

David Boyle
Mr. Boyle is Senior Vice President and Chief Financial Officer at Bionovo, Inc. and has served in this role since early 2012. He was previously Senior Vice President and Chief Financial Officer of AVI BioPharma, Inc., a Washington-based company developing RNA-based therapeutics.  Prior to AVI, he was Vice President, Finance and Chief Financial Officer of XOMA, Ltd., a California-based leader in the discovery and development of therapeutic antibodies.  In addition to his past positions as Vice President of Finance at Polycom and Director of Business Development at Intel, Mr. Boyle has held senior positions in biotechnology and specialty pharmaceutical companies.  He was previously at Salix Pharmaceuticals, Ltd. in the U.S. and at Ares Serono Group both in the U.S. and Switzerland..

Bionovo Board of Directors

Isaac Cohen, O.M.D., L.Ac.
Dr. Cohen is a co-founder of Bionovo Pharmaceuticals, Inc. (“Bionovo Pharmaceuticals”), and has served as its Chairman, Chief Executive Officer and Chief Scientific Officer and a Director since February 2002. He became the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer and a Director in April 2005. Mr. Cohen has been a Guest Scientist at the University of California, San Francisco (UCSF) Cancer Research Center and UCSF Center for Reproductive Endocrinology since 1996. Mr. Cohen was in private practice at The American Acupuncture Center, located in Berkeley, California from 1989-2005.

Mary Tagliaferri, M.D., L.Ac.
Dr. Tagliaferri is a co-founder of Bionovo Pharmaceuticals, and has served as its Chief Regulatory Officer, Chief Medical Officer, Secretary and Treasurer and as a director since February 2002. She became Vice President, Chief Medical Officer, Chief Regulatory Officer, Secretary and Treasurer of Bionovo, Inc. in April 2005, and a Director effective May 2005. She became President of Bionovo, Inc. in addition to continuing her functions as the Company’s Chief Medical Officer, Secretary, Treasurer and Director in May 2007. Dr. Tagliaferri conducted translational research at the University of California, San Francisco from 1996-2002.

Louis Drapeau
Mr. Drapeau has been a Director since March 14, 2008 and serves as our Lead Independent Director and the chair of our Audit Committee. Mr. Drapeauis has been Chief Financial Officer of InSite Vision since 2007 and served as the Company's Chief Executive Officer from November 2008 to December 2010. Prior to InSite Vision, he served as Chief Financial Officer, Senior Vice President, Finance, at Nektar Therapeutics, a biopharmaceutical company headquartered in San Carlos, California from January 2006 to August 2007. Prior to Nektar, Mr. Drapeau served as Acting Chief Executive Officer from August 2004 to May 2005 and as Senior Vice President and Chief Financial Officer from August 2002 to August 2005 for BioMarin Pharmaceutical Inc, a pharmaceutical company. Previously, Mr. Drapeau spent more than 30 years at Arthur Andersen. Mr. Drapeau also serves on the boards of Intermune, Inc., a pharmaceutical company and Bio-Rad Laboratories, a life science and clinical diagnosis company. Mr. Drapeau is an independent and unaffiliated director, and serves as the chair of our Audit Committee.

George C. Butler, Ph.D.
Dr. Butler has been a Director since March 11, 2008. Currently, Dr. Butler serves as the Chairman and President of SingEval (Singapore) Pte. Ltd., a drug development company based in Singapore and the US. Dr. Butler was formerly the vice president, Customer Relationships, Global Development of AstraZeneca, plc, a global pharmaceutical company. Prior to this, he was Vice President, head of regulatory affairs. Prior to his time at AstraZeneca, Dr. Butler was vice president and head of regulatory affairs with Novartis AG. Dr. Butler has over 30 years of healthcare research and business experience, primarily in a development environment in multiple biopharmaceutical companies and has also been active for many years in advancing Asian-Western development/regulatory single programs. Dr. Butler is an independent and unaffiliated director, and serves on our Compensation and Nominations Committee.

Robert Farrell, J.D.
Mr. Farrell held the positions of Executive Vice President and CFO of Titan Pharmaceuticals, Inc. and was appointed President and CEO of Titan in December 2008, a position that he held through 2009. Prior to Titan Pharmaceuticals, from 1991-1996, Mr. Farrell served as Corporate Group Vice President and CFO of Fresenius USA, a pharmaceutical manufacturing and medical device company focused on the treatment of end-stage renal disease. Mr. Farrell holds an undergraduate degree from the University of Notre Dame and received his J.D.degree from the University of California.